
NYSEHealthcareMedical - Instruments & Supplies
最新資料
US$366
+US$2.73 · +0.75%
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
前收盤價
US$366
+US$2.73 · +0.75%
盤中時間採用ET。市場資料可能有所延遲。
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
日內區間
目前US$366
52週區間
目前US$366
盤中時間採用ET。市場資料可能有所延遲。
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
日內區間
目前US$366
52週區間
目前US$366
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 30.74億 USD | 28.93億 USD | 29.51億 USD | 28.86億 USD | 28.31億 USD |
| 銷貨成本 | 19.7億 USD | 18.91億 USD | 18.18億 USD | 17.47億 USD | 16.57億 USD |
| 毛利 | 11.03億 USD | 10.02億 USD | 11.33億 USD | 11.39億 USD | 11.73億 USD |
| 研究與開發 | 7430萬 USD | 6910萬 USD | 6840萬 USD | 5850萬 USD | 5280萬 USD |
| 銷售、一般及管理費用 | 3.93億 USD | 3.39億 USD | 3.53億 USD | 3.17億 USD | 3.62億 USD |
| 營業費用 | 4.86億 USD | 4.08億 USD | 4.22億 USD | 3.75億 USD | 4.15億 USD |
| 利息收入 | 1770萬 USD | 1960萬 USD | 2800萬 USD | 510萬 USD | 100萬 USD |
| 利息支出 | 60萬 USD | 290萬 USD | 880萬 USD | 760萬 USD | 850萬 USD |
| 折舊和攤銷 | 1.71億 USD | 1.55億 USD | 1.37億 USD | 1.21億 USD | 1.22億 USD |
| 營業利益 | 6.17億 USD | 5.95億 USD | 7.11億 USD | 7.64億 USD | 7.59億 USD |
| 淨利 | 4.94億 USD | 4.93億 USD | 5.93億 USD | 5.86億 USD | 6.62億 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動,並非 GoAI 建議。
年度分割調整後的每股現金分配。
US$0.85
2025年(完整年度)+23.2% 自從 2021
2026年(部分年度):US$0.66
US$0.69
2,021
US$0.73
2,022
US$0.77
2,023
US$0.81
2,024
US$0.85
2,025
US$0.66
2,026*
* 在現有股息歷史記錄中,該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年7月29日 | US$0.22Quarterly | 2026年7月29日 | 2026年8月5日 |
股息 | 2026年4月29日 | US$0.22Quarterly | 2026年4月29日 | 2026年5月6日 |
股息 | 2026年1月28日 | US$0.22Quarterly | 2026年1月28日 | 2026年2月4日 |
股息 | 2025年11月12日 | US$0.22Quarterly | 2025年11月12日 | 2025年11月19日 |
股息 | 2025年7月30日 | US$0.21Quarterly | 2025年7月30日 | 2025年8月6日 |
股息 | 2025年4月30日 | US$0.21Quarterly | 2025年4月30日 | 2025年5月7日 |
除息 2026年7月29日
US$0.22
Quarterly
2026年7月29日登記 · 支付日 2026年8月5日
除息 2026年4月29日
US$0.22
Quarterly
2026年4月29日登記 · 支付日 2026年5月6日
除息 2026年1月28日
US$0.22
Quarterly
2026年1月28日登記 · 支付日 2026年2月4日
除息 2025年11月12日
US$0.22
Quarterly
2025年11月12日登記 · 支付日 2025年11月19日
除息 2025年7月30日
US$0.21
Quarterly
2025年7月30日登記 · 支付日 2025年8月6日
除息 2025年4月30日
US$0.21
Quarterly
2025年4月30日登記 · 支付日 2025年5月7日
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T497.3億0.04%129.35兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI7.66億0.03%2.3兆 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO6.4億0.04%1.8兆 USD0.03%US$715.59+0.61%
Vanguard Morningstar Mid-Cap ETFVO5.21億0.23%2264億 USD0.03%US$81.14+0.92%
iShares Core S&P 500 ETFIVV3.4億0.04%8964.4億 USD0.03%US$781.97+0.60%
Vanguard Morningstar Growth ETFVUG3.18億0.08%3846億 USD0.03%US$91.97+0.72%
State Street SPDR S&P 500 ETFSPY3.14億0.04%8172億 USD0.09%US$778.57+0.60%
Invesco S&P 500 Equal Weight ETFRSP2.13億0.22%977.83億 USD0.20%US$213.04+0.55%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
Vanguard Morningstar Growth ETFVUG
State Street SPDR S&P 500 ETFSPY
Invesco S&P 500 Equal Weight ETFRSPAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。